Thrombosis risk stratification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(10 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
{{Thrombosis}}
{{Thrombosis}}
{{CMG}} {{AE}} {{VE}}


{{CMG}}
==Overview==
'''Associate Editors-in-Chief:''' [[User:Ujjwal Rastogi|Ujjwal Rastogi, MBBS]] [mailto:urastogi@perfuse.org]
Presence of a [[thrombophilia|risk factor for thrombosis]] has an impact on the treatment of the patient. Short term anti-coagulation can be successful in the presence of a transient risk factor. Long term anti-coagulation is required in case of a persistent risk factor.


==Risk factors==
==Risk Factors==
*'''General'''
The Thrombosis formation is a phenomenon that can be elicited by various conditions, all of which take effect by means of mechanisms of  [[Virchow's triad]]. Blood stasis, endothelial defect or [[hypercoagulability]].   
 
*General
**Older age
**Older age
**Female gender
**Female gender
Line 11: Line 15:
**[[Obesity]]
**[[Obesity]]
**[[Pregnancy]]
**[[Pregnancy]]
**Immobilisation
**Immobilization


*'''Medical'''
*Medical
**Surgery
**Surgery
**[[Congestive heart failure and thrombosis|Heart failure]]
**[[Trauma]]
**[[Trauma]]
**[[Oral contraceptive]] use
**[[Oral contraceptive]] use
Line 26: Line 31:
**[[Disseminated intravascular coagulation]]
**[[Disseminated intravascular coagulation]]


*'''Familial'''
*Familial
**[[Antithrombin|Antithrombin III deficiency]]
**[[Antithrombin|Antithrombin III deficiency]]
**[[Protein C deficiency]]/[[Protein S deficiency]]
**[[Protein C deficiency]]/[[Protein S deficiency]]
Line 33: Line 38:
**Hypoplasminogenemia
**Hypoplasminogenemia
**Familial homocysteinemia
**Familial homocysteinemia
==Source==
http://www.bmj.com/content/343/bmj.d4656.full


{{Circulatory system pathology}}
==References==
{{SIB}}
{{reflist|2}}


[[Category:Hematology]]
[[Category:Hematology]]
Line 44: Line 46:
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[cs:Trombóza]]
[[de:Thrombose]]
[[eo:Trombozo]]
[[it:Trombosi]]
[[he:תרומבוס]]
[[ms:Trombotik]]
[[nl:Trombose]]
[[pt:Trombose]]
[[fi:Verihiutale]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 09:05, 29 January 2019

Thrombosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Classification

Arterial
Venous
Arterial and Venous Thrombosis: Differences and Similarities

Causes

Site of Thrombosis

Arterial
Venous

Differentiating Thrombosis from other Diseases

Arterial
Venous

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Evaluation

Treatment

Risk Factor Modifications

Prevention

Thrombosis risk stratification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombosis risk stratification

CDC onThrombosis risk stratification

Thrombosis risk stratification in the news

Blogs on Thrombosis risk stratification

to Hospitals Treating Thrombosis risk stratification

Risk calculators and risk factors for Thrombosis risk stratification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vahid Eidkhani, M.D.

Overview

Presence of a risk factor for thrombosis has an impact on the treatment of the patient. Short term anti-coagulation can be successful in the presence of a transient risk factor. Long term anti-coagulation is required in case of a persistent risk factor.

Risk Factors

The Thrombosis formation is a phenomenon that can be elicited by various conditions, all of which take effect by means of mechanisms of Virchow's triad. Blood stasis, endothelial defect or hypercoagulability.

References

Template:WH Template:WS